Bavarian Nordic Has Signed Contract with Denmark and another European NATO Country for the Delivery of IMVAMUNE® Smallpox Vaccine

Kvistgård, Denmark, June 15, 2011 - Bavarian Nordic A/S (NASDAQ OMX: BAVA) today
announced that it has signed a contract with the Danish Defence for the delivery
of  the  company's  third  generation  smallpox vaccine, IMVAMUNE®. Furthermore,
Bavarian Nordic has signed a contract with another European NATO country for the
delivery of IMVAMUNE®.

The  vaccines will be delivered in 2011. The size and value of the contracts are
undisclosed.

Like the U.S. government, which has so far ordered 20 million doses of the
vaccine, IMVAMUNE® will form part of these countries' bio-preparedness in the
event of a smallpox outbreak due to e.g. an act of terrorism. Although IMVAMUNE®
is an unlicensed vaccine, it has been made available for government purchase.
Data from more than 10 years of research indicate that IMVAMUNE® has a favorable
safety profile and is well tolerated, including in people who are not
recommended to receive the traditional smallpox vaccines, such as people with
weakened immune systems (e.g. people infected with HIV) or diagnosed with atopic
dermatitis (skin allergies).

The contracts do not affect the company's expectations for the 2011 full year
results.

Anders  Hedegaard, President & CEO comments: "Although these are smaller orders,
we believe they can be the launch pad for a long-term cooperation on building up
a modern bio-preparedness in these countries. Just like the U.S., Canada and the
other  countries which have purchased our vaccine, these countries now recognize
the  excellent features of  IMVAMUNE®, which not  only appears to  be safer, but
studies have also shown it has faster onset of protection than the old vaccines.
We  are  continuously  working  to  position  IMVAMUNE®  towards governments and
national  defences  in  other  countries  that  have shown their interest in the
vaccine."

Asger Aamund
Chairman of the Board

Contact
Anders Hedegaard, President & CEO. Phone +45 23 20 30 64


About Bavarian Nordic
Bavarian Nordic is a vaccine-focused biotechnology company developing and
producing novel vaccines for the treatment and prevention of life-threatening
diseases with a large unmet medical need. The company's clinical pipeline
targets cancer and infectious diseases, and includes seven development
programmes. Two programmes are under preparation for Phase III: PROSTVAC(®), a
therapeutic vaccine for advanced prostate cancer is being developed under a
collaboration agreement with the National Cancer Institute, and IMVAMUNE(®), a
third-generation smallpox vaccine is being developed under a contract with the
US government.

Bavarian Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA.

For more information please visit www.bavarian-nordic.com

PROSTVAC(®) is a registered trademark in the U.S.

Forward-looking statements
This announcement includes "forward-looking statements" that involve risks,
uncertainties and other factors, many of which are outside of our control that
could cause actual results to differ materially from the results discussed in
the forward-looking statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance and/or other
information that is not historical information. We undertake no obligation to
publicly update or revise forward-looking statements to reflect subsequent
events or circumstances after the date made, except as required by law.

[HUG#1523472]